For many patients, single- or first-episode pericarditis is just the beginning of their journey. Up to 30% of patients with pericarditis will experience a recurrent episode within 18 months, despite treatment with traditional therapies. Managing recurrent pericarditis (RP) can be a challenge for clinicians because pericarditis and RP are distinctly different in pathology, duration of disease, and risk of both recurrence and complications. At this Industry Expert Theater, we will review the diagnosis of RP, the underlying interleukin-1 (IL-1) pathway that drives the repetitive cycle of recurrence, insights regarding RP disease duration, and a treatment option for RP. Developed and offered by Kiniksa Pharmaceuticals Corp.
Non-CME
